Elon Musk’s Miracle Pill: The 14kg Weight Loss Secret That’s Also Turning Back the Clock on Aging
Elon Musk’s Weight Loss Secret: Wegobi Slows Down Aging and Lowers Mortality Rate
A recent study has found that Wegobi, the obesity treatment drug used by Elon Musk to lose weight, also slows down aging and lowers the mortality rate.
According to the Guardian, research results announced at the European Society of Cardiology conference in London showed that semaglutide, the main ingredient in Wegobi, reduces mortality from all causes, including cardiovascular and non-cardiovascular diseases, by 19%.
An international joint research team, including Harvard University and the University of Palermo, divided 17,604 participants aged 45 or older who were overweight or obese and had cardiovascular disease but no diabetes into a group that took semaglutide once a week and a group that took a placebo. The team observed the participants for 3 years and 4 months, during which time a total of 833 people died. The semaglutide group was found to have a 19% lower all-cause mortality rate than the placebo group.
The mortality rate due to cardiovascular disease was found to be 15% lower than the placebo group, and the mortality rate due to non-cardiovascular disease was found to be 23% lower. Semaglutide, the main ingredient in Ozempic and Wegobi, is an analogue of the hormone GLP-1, which helps promote insulin secretion and suppress appetite.
Harlan Krumholz, a professor at Yale School of Medicine who published the study results, said, “Semaglutide has broader benefits than we first imagined. It’s not just about preventing heart attacks; it’s about improving health and actually slowing down the aging process.”
Benjamin Schirica, a professor at Harvard University and the study’s lead author, added, “This supports the idea that being overweight and obese increases the risk of death from multiple causes. The robust reduction in noncardiovascular deaths, particularly deaths from infections, is striking.”
Elon Musk, the CEO of Tesla, used Wegobi to lose 14 kg and personally mentioned “intermittent fasting and Wegobi” as the secret to his diet.
Wegobi underwent clinical trials in Korea and received approval from the Ministry of Food and Drug Safety in April. A review is currently underway regarding whether health insurance will be applied, and the domestic launch is scheduled for the first half of next year at the latest.